Colorectal cancer patients with PIK3CA mutations compared to wt PIK3CA demonstrated a trend to a shorter median PFS to the last FDA-approved therapy (2.8 months [1.6-4.0] vs. 4.3 months [3.3-5.3]; p=0.10) (Table 3). This evidence concerns the gene PIK3CA and colorectal cancer.